Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Merck opted to license its second TriNKET immunotherapy candidate from Dragonfly Therapeutics. The option came one year after Merck licensed its first immunotherapy candidate.
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
Compounds in these Peptides may be suitable for the treatment of cancers in which extracellular matrix metalloprotease (“MMP”) or other proteinases such as urokinase-type plasminogen activator (uPa) are implicated.
Although vaccines and effective therapeutics are powerful tools in preventing and treating COVID-19, we’re not done battling the disease just yet. For those stories and more, read on.
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
Shares of Kura Oncology have plunged nearly 30% in premarket trading after the FDA placed a partial clinical hold on the company’s Phase Ib leukemia study following the report of a patient’s death.
The FDA approved Takeda’s Livtencity (maribavir) for adults and children 12 years or older with post-transplant cytomegalovirus (CMV) infection.
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash.
A preprint in bioRxiv from Penn State showed SARS-CoV-2 was detected in 33% (94) of the 283 white-tailed deer tested in Iowa between November 23, 2020 and January 10, 2021.
Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics.
Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.